{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:24:55Z","timestamp":1760059495390,"version":"build-2065373602"},"reference-count":24,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T00:00:00Z","timestamp":1750118400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: The use of antiseizure medications (ASMs) during pregnancy is critical to seizure control in women with epilepsy but raises concerns regarding the use of these drugs and their possible effect on the maternal serum biochemical markers used for second-trimester prenatal screening. The aim of this study was to assess the effect of ASMs on the levels of maternal serum alpha-fetoprotein (AFP), unconjugated estriol (uE3), and human chorionic gonadotropin (hCG) assessed in the serum biomarker analyses part of second-trimester prenatal screening. Materials and Methods: This retrospective cohort study included 43 pregnant women in the ASM-exposed group (levetiracetam, lamotrigine, carbamazepine, or combined therapy) and 43 matched controls without medication use. Groups were matched based on maternal age, gravidity, parity, abortion history, gestational age at testing, body mass index, and smoking status with propensity score matching. Serum AFP, uE3, and hCG levels measured at 15\u201320 weeks of gestation were compared between groups. The incidence of fetal congenital anomalies or aneuploidies was also compared between groups. Results: Pregnant women in the ASM-exposed group had significantly higher maternal serum AFP (1.34 \u00b1 0.42 vs. 1.01 \u00b1 0.31 MoM; p &lt; 0.001) and uE3 (1.28 \u00b1 0.39 vs. 1.05 \u00b1 0.34 MoM; p = 0.004) than the controls. However, hCG did not differ significantly between the groups (1.07 \u00b1 0.46 vs. 1.01 \u00b1 0.42 MoM; p = 0.523). Regarding the ASM subgroups (levetiracetam, lamotrigine, and carbamazepine), there were no significant differences in the serum biomarkers (p &gt; 0.05). There was no significant difference between the ASM-exposed and control groups in terms of the incidence of congenital anomalies or aneuploidies (2.3% in the ASM-exposed group vs. 2.3% in the control group; p = 1.000). Conclusions: The use of ASMs during pregnancy significantly alters second-trimester maternal serum biochemical markers, including our primary concerns, AFP and uE3, which could cause inaccurate interpretations of second-trimester prenatal screening. Clinicians should carefully consider maternal medication exposure when interpreting these biochemical markers in pregnant women with epilepsy to prevent the misclassification of fetal risks and avoid unnecessary invasive procedures.<\/jats:p>","DOI":"10.3390\/medicina61061101","type":"journal-article","created":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T10:45:26Z","timestamp":1750157126000},"page":"1101","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effects of Antiseizure Medications on Second-Trimester Prenatal Screening Test Parameters: A Retrospective Cohort Study"],"prefix":"10.3390","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0008-4078","authenticated-orcid":false,"given":"Melisa","family":"Golgelioglu","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynaecology, Yozgat City Hospital, 66100 Yozgat, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cigdem","family":"Akcabay","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynaecology, Faculty of Medicine, F\u0131rat University, 23119 Elazig, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gunes Seda","family":"Albayrak","sequence":"additional","affiliation":[{"name":"Department of Neurology, Faculty of Medicine, Yozgat Bozok University, 66100 Yozgat, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Selda","family":"Telo","sequence":"additional","affiliation":[{"name":"Biochemistry and Clinical Biochemistry, Faculty of Medicine, F\u0131rat University, 23119 Elazig, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,6,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1212\/WNL.0000000000003509","article-title":"Prevalence and incidence of epilepsy: A systematic review and meta-analysis of international studies","volume":"88","author":"Fiest","year":"2017","journal-title":"Neurology"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/WCO.0000000000000659","article-title":"Teratogenicity of antiepileptic drugs","volume":"32","author":"Tomson","year":"2019","journal-title":"Curr. Opin. Neurol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1586\/14737175.2015.1083422","article-title":"Management of epilepsy during pregnancy","volume":"15","author":"Voinescu","year":"2015","journal-title":"Expert Rev. Neurother."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1111\/j.1528-1167.2009.02128.x","article-title":"Management issues for women with epilepsy\u2014Focus on pregnancy (an evidence-based review): I. Obstetrical complications and change in seizure frequency","volume":"50","author":"Harden","year":"2009","journal-title":"Epilepsia"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1080\/15513815.2018.1502381","article-title":"First and second trimester biochemical markers in maternal epilepsy: A case-control study","volume":"37","author":"Oksuzoglu","year":"2018","journal-title":"Fetal Pediatr. Pathol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1111\/jog.15250","article-title":"Effect of antiepileptic drugs on serum biochemical marker levels of first and second trimester screening tests","volume":"48","author":"Besimoglu","year":"2022","journal-title":"J. Obstet. Gynaecol. Res."},{"key":"ref_7","first-page":"CD009925","article-title":"Second trimester serum tests for Down\u2019s Syndrome screening","volume":"2012","author":"Alldred","year":"2012","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"114","DOI":"10.11613\/BM.2017.015","article-title":"Proficiency testing of maternal serum prenatal screening in second trimester in China, 2015","volume":"27","author":"Zhang","year":"2017","journal-title":"Biochem. Med."},{"key":"ref_9","first-page":"281","article-title":"Correlation of pregnancy outcome with quadruple screening test at second trimester","volume":"29","author":"Yazdani","year":"2015","journal-title":"Med. J. Islam. Repub. Iran."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Pranpanus, S., Kor-Anantakul, O., Suntharasaj, T., Suwanrath, C., Hanprasertpong, T., Pruksanusak, N., Petpichetchian, C., Suksai, M., Chainarong, N., and Sawaddisan, R. (2021). Ethnic-specific reference range affects the efficacy of quadruple test as a universal screening for Down syndrome in a developing country. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0251381"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"765","DOI":"10.3109\/00498254.2015.1118774","article-title":"Evaluation of cytochrome P450 inductions by anti-epileptic drug oxcarbazepine, 10-hydroxyoxcarbazepine, and carbamazepine using human hepatocytes and HepaRG cells","volume":"46","author":"Sugiyama","year":"2016","journal-title":"Xenobiotica"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Kuchnowska, D., Stachura, A., Kosinski, P., Gawlak, M., and Wegrzyn, P. (2024). Accuracy of estimated fetal weight assessment in fetuses with congenital diaphragmatic hernia\u2014Is the Hadlock formula a reliable tool?. J. Clin. Med., 13.","DOI":"10.3390\/jcm13123392"},{"key":"ref_13","first-page":"30","article-title":"Antiepileptic drugs carbamazepine and valproic acid mediate transcriptional activation of CYP1A1 via aryl hydrocarbon receptor and regulation of estrogen metabolism","volume":"271","author":"Chen","year":"2017","journal-title":"Toxicol. Lett."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies","volume":"46","author":"Austin","year":"2011","journal-title":"Multivariate Behav. Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/epi.18338","article-title":"Updated Classification of Epileptic Seizures: Position Paper of the International League Against Epilepsy","volume":"66","author":"Beniczky","year":"2025","journal-title":"Epilepsia"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1212\/01.WNL.0000103286.47129.F8","article-title":"The impact of pregnancy and childbirth on the metabolism of lamotrigine","volume":"62","author":"Pennell","year":"2004","journal-title":"Neurology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1111\/j.1528-1167.2007.01032.x","article-title":"Pharmacokinetics of levetiracetam during pregnancy, delivery, in the neonatal period, and lactation","volume":"48","author":"Tomson","year":"2007","journal-title":"Epilepsia"},{"key":"ref_18","first-page":"145","article-title":"Maternal cigarette smoking during pregnancy and risk of congenital abnormalities in offspring","volume":"40","author":"Banhidy","year":"2011","journal-title":"Int. J. Epidemiol."},{"key":"ref_19","first-page":"362","article-title":"The influence of maternal weight on maternal serum biochemical marker concentrations in the second trimester","volume":"31","author":"Spencer","year":"2011","journal-title":"Prenat. Diagn."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1002\/pd.2505","article-title":"Prediction of adverse pregnancy outcomes by combinations of first and second trimester biochemistry markers used in maternal serum screening","volume":"30","author":"Huang","year":"2010","journal-title":"Prenat. Diagn."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e209279","DOI":"10.1212\/WNL.0000000000209279","article-title":"Teratogenesis, Perinatal, and Neurodevelopmental Outcomes After In Utero Exposure to Antiseizure Medication: Practice Guideline From the AAN, AES, and SMFM","volume":"102","author":"Pack","year":"2024","journal-title":"Neurology"},{"key":"ref_22","first-page":"e1664","article-title":"Practice guideline update summary: Management issues for women with epilepsy\u2014Focus on pregnancy (an evidence-based review): Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy Society","volume":"90","author":"Meador","year":"2018","journal-title":"Neurology"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1186\/s12884-018-1842-x","article-title":"Sodium valproate in pregnancy: What are the risks and should we use a shared decision-making approach?","volume":"18","author":"Macfarlane","year":"2018","journal-title":"BMC Pregnancy Childbirth"},{"key":"ref_24","first-page":"CD010224","article-title":"Monotherapy treatment of epilepsy in pregnancy: Congenital malformation outcomes in the child","volume":"2014","author":"Bromley","year":"2014","journal-title":"Cochrane Database Syst. Rev."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/6\/1101\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:53:37Z","timestamp":1760032417000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/6\/1101"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,17]]},"references-count":24,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["medicina61061101"],"URL":"https:\/\/doi.org\/10.3390\/medicina61061101","relation":{},"ISSN":["1648-9144"],"issn-type":[{"type":"electronic","value":"1648-9144"}],"subject":[],"published":{"date-parts":[[2025,6,17]]}}}